{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:20:06Z","timestamp":1758846006590,"version":"3.44.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.clp.2011.12.008","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T16:32:55Z","timestamp":1326299575000},"page":"83-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Use of Antifungal Therapy in Neonatal Intensive Care"],"prefix":"10.1016","volume":"39","author":[{"given":"Daniela","family":"Testoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib1","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1542\/peds.2009-3412","article-title":"Neonatal candidiasis: epidemiology, risk factors, and clinical judgment","volume":"126","author":"Benjamin","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.idc.2005.05.007","article-title":"Neonatal candidiasis","volume":"19","author":"Smith","year":"2005","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.2004-2292","article-title":"Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months","volume":"117","author":"Benjamin","year":"2006","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.inf.0000253973.89097.c0","article-title":"Excess costs of hospital care associated with neonatal candidemia","volume":"26","author":"Smith","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.jp.7211628","article-title":"Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures","volume":"27","author":"Cohen-Wolkowiez","year":"2007","journal-title":"J\u00a0Perinatol"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/313973","article-title":"Candidal meningitis in neonates: a 10-year review","volume":"31","author":"Fernandez","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.clp.2011.12.008_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.112.3.634","article-title":"Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques","volume":"112","author":"Benjamin","year":"2003","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.clp.2011.12.008_bib8","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.earlhumdev.2011.01.014","article-title":"Pharmacokinetics of antifungal agents in children","volume":"87","author":"Watt","year":"2011","journal-title":"Early Hum Dev"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib9","doi-asserted-by":"crossref","first-page":"F164","DOI":"10.1136\/adc.2009.178996","article-title":"Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants","volume":"96","author":"Aydemir","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"23","key":"10.1016\/j.clp.2011.12.008_bib10","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMoa010494","article-title":"Fluconazole prophylaxis against fungal colonization and infection in preterm infants","volume":"345","author":"Kaufman","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1542\/peds.107.2.293","article-title":"Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant","volume":"107","author":"Kicklighter","year":"2001","journal-title":"Pediatrics"},{"issue":"24","key":"10.1016\/j.clp.2011.12.008_bib12","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa065733","article-title":"A\u00a0multicenter, randomized trial of prophylactic fluconazole in preterm neonates","volume":"356","author":"Manzoni","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib13","first-page":"830","article-title":"Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants","volume":"44","author":"Parikh","year":"2007","journal-title":"Indian Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3349\/ymj.2007.48.4.619","article-title":"A\u00a0comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants","volume":"48","author":"Jeon","year":"2007","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3476(05)82674-5","article-title":"Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates","volume":"116","author":"Baley","year":"1990","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib17","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1542\/peds.113.6.e608","article-title":"Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants","volume":"113","author":"Holler","year":"2004","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1542\/peds.107.1.61","article-title":"Review of 49 neonates with acquired fungal sepsis: further characterization","volume":"107","author":"Makhoul","year":"2001","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e3181af6201","article-title":"Nephrotoxicity associated with amphotericin B deoxycholate in neonates","volume":"28","author":"Le","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations","volume":"52","author":"Linder","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1\u20132","key":"10.1016\/j.clp.2011.12.008_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-5173(02)00066-2","article-title":"A\u00a0comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates","volume":"238","author":"Kotwani","year":"2002","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.38.4.713","article-title":"Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits","volume":"38","author":"Lee","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib23","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1128\/AAC.49.12.5092-5098.2005","article-title":"Population pharmacokinetics of amphotericin B lipid complex in neonates","volume":"49","author":"Wurthwein","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-003-0993-4","article-title":"High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates","volume":"22","author":"Juster-Reicher","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.42.3.606","article-title":"Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion","volume":"42","author":"Anaissie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","article-title":"Flucytosine","volume":"86","author":"Bennet","year":"1977","journal-title":"Ann Intern Med"},{"issue":"3-4","key":"10.1016\/j.clp.2011.12.008_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"1975","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","article-title":"Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis","volume":"6","author":"Smego","year":"1984","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000007260","article-title":"Flucytosine: correlation between toxicity and pharmacokinetic parameters","volume":"46","author":"Vermes","year":"2000","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ijantimicag.2006.07.013","article-title":"Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory","volume":"28","author":"Soltani","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-113-3-177","article-title":"Fluconazole, a new antifungal agent","volume":"113","author":"Galgiani","year":"1990","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.clp.2011.12.008_bib34","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V62242","article-title":"Pharmacokinetics of fluconazole in renal failure","volume":"6","author":"Berl","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01974613","article-title":"Pharmacokinetics of fluconazole in pediatric patients","volume":"13","author":"Brammer","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib37","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population pharmacokinetics of fluconazole in young infants","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/JCM.42.4.1519-1527.2004","article-title":"Incidence of bloodstream infections due to Candida species and in\u00a0vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program","volume":"42","author":"Hajjeh","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/INF.0b013e31819f1f50","article-title":"Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants","volume":"28","author":"Wade","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/INF.0b013e318202cbb3","article-title":"Fluconazole loading dose pharmacokinetics and safety in infants","volume":"30","author":"Piper","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF03190361","article-title":"Pharmacokinetics of fluconazole in young infants","volume":"24","author":"Nahata","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7\u20138","key":"10.1016\/j.clp.2011.12.008_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1439-0507.1997.tb00230.x","article-title":"Fluconazole: comparison of pharmacokinetics, therapy and in\u00a0vitro susceptibility","volume":"40","author":"Wildfeuer","year":"1997","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib43","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.43.8.1955","article-title":"Safety and tolerability of fluconazole in children","volume":"43","author":"Novelli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2005.03.036","article-title":"Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight","volume":"147","author":"Kaufman","year":"2005","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/INF.0b013e3181bf8eb1","article-title":"Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants","volume":"29","author":"Aziz","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2005.02.020","article-title":"Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants","volume":"147","author":"Bertini","year":"2005","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1542\/peds.2007-1130","article-title":"Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species","volume":"121","author":"Healy","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib48","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1542\/peds.2004-2227","article-title":"Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study","volume":"117","author":"Manzoni","year":"2006","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib49","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/adc.2006.094359","article-title":"Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection","volume":"92","author":"McCrossan","year":"2007","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib50","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/INF.0b013e3181e9dea2","article-title":"Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country","volume":"29","author":"Rueda","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.jp.7211914","article-title":"Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure","volume":"28","author":"Weitkamp","year":"2008","journal-title":"J\u00a0Perinatol"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/INF.0b013e318170bb0c","article-title":"Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies","volume":"27","author":"Manzoni","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib54","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib55","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib56","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.01731-09","article-title":"Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients","volume":"54","author":"Michael","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","article-title":"Voriconazole plasma levels in children are highly variable","volume":"30","author":"Spriet","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.clp.2011.12.008_bib58","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0b013e318204d227","article-title":"Impact of therapeutic drug monitoring of voriconazole in a pediatric population","volume":"30","author":"Bruggemann","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.clp.2011.12.008_bib60","unstructured":"Doby EH, Benjamin DK Jr, Blaschke AJ, et\u00a0al. Therapeutic drug monitoring of voriconazole in children less than 3 years of age: a case report and summary of pharmacokinetic data for 10 children. Pediatr Infect Dis J, in press."},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.0736-8046.2004.21614.x","article-title":"Voriconazole-induced retinoid-like photosensitivity in children","volume":"21","author":"Rubenstein","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.clp.2011.12.008_bib63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib64","first-page":"236","article-title":"Voriconazole in newborns","volume":"45","author":"Kohli","year":"2008","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0924-8579(01)00363-6","article-title":"In\u00a0vitro antifungal activity of posaconazole against various pathogenic fungi","volume":"18","author":"Uchida","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib66","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","article-title":"In\u00a0vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.clp.2011.12.008_bib67","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.clp.2011.12.008_bib68","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: a multicentre survey","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib70","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib71","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"9390","key":"10.1016\/j.clp.2011.12.008_bib72","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates","volume":"197","author":"Hope","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib74","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1128\/AAC.00646-09","article-title":"Anidulafungin treatment of candidal central nervous system infection in a murine model","volume":"53","author":"Kang","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","article-title":"In\u00a0vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7164\/antibiotics.55.219","article-title":"Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus","volume":"55","author":"Hatano","year":"2002","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1130-1406(09)70009-9","volume":"26","author":"Infante-Lopez","year":"2009","journal-title":"Rev Iberoam Micol"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib78","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/cc8117","article-title":"Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B","volume":"13","author":"Dupont","year":"2009","journal-title":"Crit Care"},{"issue":"9572","key":"10.1016\/j.clp.2011.12.008_bib79","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clp.2011.12.008_bib80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib81","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.clp.2011.12.008_bib82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib83","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/AAC.45.12.3322-3327.2001","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib84","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10156-011-0240-3","article-title":"Distribution of micafungin in the tissue fluids of patients with invasive fungal infections","volume":"17","author":"Yamada","year":"2011","journal-title":"J\u00a0Infect Chemother"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib85","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.clp.2011.12.008_bib86","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/bdd.752","article-title":"Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding","volume":"32","author":"Yanni","year":"2011","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib89","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/clpt.2009.200","article-title":"Safety and pharmacokinetics of repeat-dose micafungin in young infants","volume":"87","author":"Benjamin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib90","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib91","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/jp.2008.197","article-title":"Hepatitis associated with micafungin use in a preterm infant","volume":"29","author":"King","year":"2009","journal-title":"J\u00a0Perinatol"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib92","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib93","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/jp.2009.75","article-title":"Refractory neonatal candidemia and high-dose micafungin pharmacotherapy","volume":"29","author":"Natarajan","year":"2009","journal-title":"J\u00a0Perinatol"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib94","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1128\/AAC.49.11.4795-4797.2005","article-title":"Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis","volume":"49","author":"Pfaller","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib95","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/QAI.0b013e31817af47a","article-title":"A\u00a0phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis","volume":"48","author":"Vazquez","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"24","key":"10.1016\/j.clp.2011.12.008_bib96","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib97","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.clp.2011.12.008_bib98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","article-title":"Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment","volume":"47","author":"Dowell","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.clp.2011.12.008_bib100","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1128\/AAC.01596-07","article-title":"Pharmacokinetics and tissue distribution of anidulafungin in rats","volume":"52","author":"Damle","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib101","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2011.26","article-title":"Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates","volume":"89","author":"Cohen-Wolkowiez","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkq545","article-title":"Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration","volume":"66","author":"Leitner","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.clp.2011.12.008_bib103","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/AAC.41.7.1612","article-title":"In\u00a0vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species","volume":"41","author":"Vazquez","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.clp.2011.12.008_bib105","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A\u00a0randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib106","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.clp.2011.12.008_bib107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.clp.2011.12.008_bib108","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270007303764","article-title":"Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations","volume":"47","author":"Mistry","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.clp.2011.12.008_bib109","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age","volume":"53","author":"Saez-Llorens","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clp.2011.12.008_bib111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-7-28","article-title":"Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients","volume":"7","author":"Cesaro","year":"2007","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib112","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/01.inf.0000246844.42159.a0","article-title":"Efficacy and safety of caspofungin therapy in children with invasive fungal infections","volume":"25","author":"Merlin","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.clp.2011.12.008_bib113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A\u00a0prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.clp.2011.12.008_bib114","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A\u00a0randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.clp.2011.12.008_bib115","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.01027-08","article-title":"Pharmacokinetics and safety of caspofungin in older infants and toddlers","volume":"53","author":"Neely","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.clp.2011.12.008_bib116","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.jp.7211380","article-title":"Experience with caspofungin in the treatment of persistent fungemia in neonates","volume":"25","author":"Natarajan","year":"2005","journal-title":"J\u00a0Perinatol"},{"issue":"2","key":"10.1016\/j.clp.2011.12.008_bib117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2005.04.016","article-title":"Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit","volume":"147","author":"Healy","year":"2005","journal-title":"J\u00a0Pediatr"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510811001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510811001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:55:49Z","timestamp":1758815749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510811001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0095510811001357"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2011.12.008","relation":{},"ISSN":["0095-5108"],"issn-type":[{"type":"print","value":"0095-5108"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Antifungal Therapy in Neonatal Intensive Care","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2011.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}